SCHEMBL22855775

SCHEMBL22855775

COCCOC1C(OC)C(COC)OC1n1cnc2c(N)ncnc21

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA1 P30542 3/20 0.52
▸ ADORA3 P0DMS8 2/20 0.52
▸ P2RY1 P47900 4/20 0.51
▸ SMN1; SMN2 Q16637 3/20 0.51
▸ P2RY2 P41231 3/20 0.51
▸ SRC P12931 2/20 0.51
▸ DNPH1 O43598 1/20 0.51
▸ PRKAB2 O43741 1/20 0.51
▸ TRPM2 O94759 1/20 0.51
▸ LDHA P00338 1/20 0.51
▸ ADRB2 P07550 1/20 0.51
▸ FBP1 P09467 1/20 0.51
▸ PRKAG1 P54619 1/20 0.51
▸ PRKAA2 P54646 1/20 0.51
▸ PDE4D Q08499 1/20 0.51
▸ KCNH2 Q12809 1/20 0.51
▸ PRKAA1 Q13131 1/20 0.51
▸ PDE3A Q14432 1/20 0.51
▸ TAS1R3 Q7RTX0 1/20 0.51
▸ TAS1R1 Q7RTX1 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12590110 1.00 ADORA1 (0.52) ADORA1ADORA3P2RY1SMN1; SMN2P2RY2
SCHEMBL12646696 1.00 ADORA1 (0.52) ADORA1ADORA3P2RY1SMN1; SMN2P2RY2
SCHEMBL12015179 1.00 ADORA1 (0.52) ADORA1ADORA3P2RY1SMN1; SMN2P2RY2
SCHEMBL21999054 0.92 ADORA3 (0.56) ADORA1ADORA3P2RY1SMN1; SMN2P2RY2
SCHEMBL12376385 0.92 ADORA3 (0.56) ADORA1ADORA3P2RY1SMN1; SMN2P2RY2
SCHEMBL12360836 0.92 ADORA3 (0.56) ADORA1ADORA3P2RY1SMN1; SMN2P2RY2
SCHEMBL16587677 0.92 GAA (0.52) ADORA1ADORA3P2RY1SMN1; SMN2P2RY2
SCHEMBL24264106 0.91 ADORA1 (0.61) ADORA1ADORA3P2RY1SMN1; SMN2P2RY2
SCHEMBL19522902 0.90 EHMT1 (0.53) ADORA1ADORA3P2RY1SMN1; SMN2P2RY2
SCHEMBL22855712 0.89 AHCY (0.49) ADORA1ADORA3P2RY1SMN1; SMN2P2RY2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11166976-B2 S-antigen transport inhibiting oligonucleotide polymers and methods ALIGOS THERAPEUTICS, INC. (US) 2021-11-09 — — US disclosed
US-20200405743-A1 S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS ALIGOS THERAPEUTICS, INC. 2020-12-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11166976-B2 S-antigen transport inhibiting oligonucleotide polymers and methods RNGTT, PHAX, HAVCR2 ADORA1 1419/4885ADORA3 1372/4885P2RY1 3344/4885
US-20200405743-A1 S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS RNGTT, PHAX, HAVCR2 ADORA1 1419/4885ADORA3 1372/4885P2RY1 3344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback